de Leon Mony J, Pirraglia Elizabeth, Osorio Ricardo S, Glodzik Lidia, Saint-Louis Les, Kim Hee-Jin, Fortea Juan, Fossati Silvia, Laska Eugene, Siegel Carole, Butler Tracy, Li Yi, Rusinek Henry, Zetterberg Henrik, Blennow Kaj
Department of Psychiatry, Center for Brain Health, NYU Medical Center, New York, New York, United States of America.
Department of Population Health, Division of Biostatistics, NYU Medical Center, New York, New York, United States of America.
PLoS One. 2018 Feb 7;13(2):e0191240. doi: 10.1371/journal.pone.0191240. eCollection 2018.
Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1-42 (Aβ42) are reduced and tau levels increased prior to the onset of cognitive decline related to Alzheimer's disease (AD). However, the preclinical prediction accuracy for low CSF Aβ42 levels, a surrogate for brain Aβ42 deposits, is not high. Moreover, the pathology data suggests a course initiated by tauopathy contradicting the contemporary clinical view of an Aβ initiated cascade. CSF Aβ42 and tau data from 3 normal aging cohorts (45-90 years) were combined to test both cross-sectional (n = 766) and longitudinal (n = 651) hypotheses: 1) that the relationship between CSF levels of Aβ42 and tau are not linear over the adult life-span; and 2) that non-linear models improve the prediction of cognitive decline. Supporting the hypotheses, the results showed that a u-shaped quadratic fit (Aβ2) best describes the relationship for CSF Aβ42 with CSF tau levels. Furthermore we found that the relationship between Aβ42 and tau changes with age-between 45 and 70 years there is a positive linear association, whereas between 71 and 90 years there is a negative linear association between Aβ42 and tau. The quadratic effect appears to be unique to Aβ42, as Aβ38 and Aβ40 showed only positive linear relationships with age and CSF tau. Importantly, we observed the prediction of cognitive decline was improved by considering both high and low levels of Aβ42. Overall, these data suggest an earlier preclinical stage than currently appreciated, marked by CSF elevations in tau and accompanied by either elevations or reductions in Aβ42. Future studies are needed to examine potential mechanisms such as failing CSF clearance as a common factor elevating CSF Aβxx analyte levels prior to Aβ42 deposition in brain.
脑脊液(CSF)研究一直表明,在与阿尔茨海默病(AD)相关的认知衰退发作之前,脑脊液中β淀粉样蛋白1-42(Aβ42)水平降低,而tau蛋白水平升高。然而,低脑脊液Aβ42水平(脑Aβ42沉积的替代指标)的临床前预测准确性并不高。此外,病理学数据表明疾病进程由tau蛋白病引发,这与当前认为由Aβ引发级联反应的临床观点相矛盾。来自3个正常衰老队列(45 - 90岁)的脑脊液Aβ42和tau数据被合并,以检验横断面(n = 766)和纵向(n = 651)假设:1)在成年期,脑脊液Aβ42和tau水平之间的关系不是线性的;2)非线性模型可改善对认知衰退的预测。支持这些假设的结果表明,u形二次拟合(Aβ2)最能描述脑脊液Aβ42与脑脊液tau水平之间的关系。此外,我们发现Aβ42与tau之间的关系随年龄变化 - 在45至70岁之间存在正线性关联,而在71至90岁之间Aβ42与tau之间存在负线性关联。二次效应似乎是Aβ42所特有的,因为Aβ38和Aβ40与年龄和脑脊液tau仅呈现正线性关系。重要的是,我们观察到通过同时考虑Aβ42的高水平和低水平,对认知衰退的预测得到了改善。总体而言,这些数据表明存在一个比目前所认识到的更早的临床前期阶段,其特征是脑脊液tau升高,并伴有Aβ42升高或降低。未来需要开展研究来检查潜在机制,例如脑脊液清除功能障碍,这可能是在脑内Aβ42沉积之前导致脑脊液Aβxx分析物水平升高的一个共同因素。